Sun Pharma fired sales reps after they refused to tout drugs off-label, lawsuits say

Sun Pharma sign
Sun Pharma is facing claims it fired two employees for not cooperating with an illegal off-label marketing scheme. (Sun Pharma)

Sun Pharma is no stranger to controversy. But after fighting insider trading allegations, Sun is facing a new challenge: In two lawsuits, former salespeople claim executives fired them for refusing to market drugs off-label.

Attorneys for Sandra Hagenbrock, a former national account director for Sun, claimed her superiors directed her to tout unapproved uses of prostate cancer med Yonsa, a practice Hagenbrock said violated the False Claims Act. After refusing to follow orders, Hagenbrock said, she was fired.

The lawsuit is the second in four months filed against Sun on similar claims. In July, former employee Damian Fritz said management pushed him to market off-label uses for Yonsa as well as psoriasis med Ilumya and acne treatment Absorica. 

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Both suits specifically targeted Sun's associate vice president of sales, Janet Sharp, who allegedly directed both Hagenbrock and Fritz to "talk off-label" about the company's drugs. To back up the scheme, Fritz claimed, Sun's executives "instructed its sales members not to put such solicitations in writing, but to make the pitch in person, over the phone, or in any untraceable manner."

A Sun spokesman said the allegations in the two lawsuits were "without merit" and pledged to "vigorously defend" itself. 

RELATED: Sun Pharma drops to 6-year low on report of another whistleblower complaint

The newest claims against Sun come nearly a year after a pair of whistleblower complaints of insider trading sent the drugmaker's stock tumbling to a six-year low. 

In January, a whistleblower alleged in a 172-page complaint that dubious transactions amounting to more than Rs 5,800 crore ($816 million) took place between Sun distributor Aditya Medisales and Suraksha Realty, a firm controlled by Sun director Sudhir Valia, financial news site Moneylife said. Valia is also Sun helmsman Dilip Shanghvi’s brother-in-law.

The January complaint was the second stemming from the same whistleblower, whose initial allegations were confirmed by India’s Securities and Exchange Board of India (SEBI) in December. The first complaint accused Sun of insider trading in its acquisition of Ranbaxy.

RELATED: Sun Pharma answers complaints with revamp that cuts ties with director's firm

In 2017, Sun, Shanghvi, Valia, former Ranbaxy CEO Arun Sawhney and several other Daiichi and Sun execs paid SEBI Rs 18 lakh ($25,500) to settle charges of insider trading without admitting wrongdoing.

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.